Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-493, a Melanocortin 4 Receptor (MC4R) Agonist in Obese Patients

NCT01749137 is registered in ClinicalTrials.gov with Rhythm Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01749137
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01749137 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-493, a Melanocortin 4 Receptor (MC4R) Agonist in Obese Patients
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 14, 2013
Completion date
September 28, 2013
Enrollment
74 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

overweight